The U.S. Food and Drug Administration accepted Zhejiang Xianju Pharmaceutical's (SHE:002332) abbreviated new drug application for progesterone vaginal tablets, according to a Wednesday filing with the Shenzhen bourse.
The tablets help support embryo implantation and early pregnancy by supporting luteal function, according to the filing.